Russell Investments Group
FATE icon

Russell Investments Group’s Fate Therapeutics FATE Stock Holding History

Russell Investments Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
105,802
+96,071
+987% +$178K ﹤0.01% 3036
2026
Q1 		$11.7K Buy
9,731
+431
+5% +$525 ﹤0.01% 3762
2025
Q4 		$9.14K Sell
9,300
-19,376
-68% -$23.3K ﹤0.01% 3823
2025
Q3 		$36.1K Buy
28,676
+12,114
+73% +$13.1K ﹤0.01% 3401
2025
Q2 		$18.5K Sell
16,562
-62,815
-79% -$73K ﹤0.01% 3207
2025
Q1 		$62.7K Sell
79,377
-10,446
-12% -$12.8K ﹤0.01% 2853
2024
Q4 		$148K Buy
89,823
+26,953
+43% +$67.9K ﹤0.01% 2606
2024
Q3 		$220K Sell
62,870
-39,063
-38% -$152K ﹤0.01% 2491
2024
Q2 		$334K Sell
101,933
-8,315
-8% -$36.4K ﹤0.01% 2341
2024
Q1 		$809K Sell
110,248
-123,500
-53% -$764K ﹤0.01% 2049
2023
Q4 		$874K Buy
233,748
+59,267
+34% +$140K ﹤0.01% 2021
2023
Q3 		$370K Sell
174,481
-12,995
-7% -$43.1K ﹤0.01% 2326
2023
Q2 		$892K Buy
187,476
+15,386
+9% +$84.9K ﹤0.01% 1991
2023
Q1 		$981K Buy
172,090
+171,561
+32,431% +$1.04M ﹤0.01% 1972
2022
Q4 		$5.34K Hold
529
– – ﹤0.01% 2862
2022
Q3 		$11K Hold
529
– – ﹤0.01% 2854
2022
Q2 		$13K Hold
529
– – ﹤0.01% 2830
2022
Q1 		$20K Hold
529
– – ﹤0.01% 2681
2021
Q4 		$30K Hold
529
– – ﹤0.01% 2928
2021
Q3 		$31K Sell
529
-4,395
-89% -$345K ﹤0.01% 2975
2021
Q2 		$427K Sell
4,924
-33,812
-87% -$2.72M ﹤0.01% 2662
2021
Q1 		$3.19M Sell
38,736
-20,912
-35% -$2M 0.01% 1602
2020
Q4 		$5.43M Sell
59,648
-8,603
-13% -$534K 0.01% 1200
2020
Q3 		$2.73M Hold
68,251
– – 0.01% 1493
2020
Q2 		$2.34M Sell
68,251
-30,827
-31% -$919K 0.01% 1540
2020
Q1 		$2.2M Sell
99,078
-58,280
-37% -$1.47M 0.01% 1419
2019
Q4 		$3.08M Buy
157,358
+66,681
+74% +$1.06M 0.01% 1487
2019
Q3 		$1.41M Buy
+90,677
New +$1.74M ﹤0.01% 1849
2017
Q4 		– Sell
-59,168
Closed -$234K – 2968
2017
Q3 		$234K Buy
+59,168
New +$201K ﹤0.01% 2640

Other funds holding FATE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return

Russell Investments Group's FATE Position: Q2 2026 in Review

Russell Investments Group increased its Fate Therapeutics (FATE) stake by 987% in Q2 2026, buying an estimated $178K and bringing the position to 105,802 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #3036.

Russell Investments Group first reported a position in FATE in Q3 2017 and has held it in 29 quarters since. The position peaked at $5.43M in Q4 2020. 53 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Russell Investments Group held 105,802 shares of Fate Therapeutics worth $286K as of Q2 2026.
  • Russell Investments Group bought 96,071 Fate Therapeutics shares in Q2 2026, an estimated $178K.
  • Fate Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3036 holding.
  • Russell Investments Group first reported a position in Fate Therapeutics in Q3 2017 and has held it in 29 quarters since.
  • Russell Investments Group's Fate Therapeutics position peaked at $5.43M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.